US 12,422,427 B2
Compounds for treatment of diseases and methods of screening therefor
Anthony A. Hyman, Dresden (DE); Richard J. Wheeler, Oxford (GB); and Marc Bickle, Dresden (DE)
Assigned to Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Munich (DE)
Filed by Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Munich (DE)
Filed on Oct. 15, 2019, as Appl. No. 16/653,874.
Application 16/653,874 is a continuation of application No. PCT/EP2019/077818, filed on Oct. 14, 2019.
Claims priority of application No. 18200401 (EP), filed on Oct. 15, 2018; and application No. 19189772 (EP), filed on Aug. 2, 2019.
Prior Publication US 2020/0150107 A1, May 14, 2020
Int. Cl. G01N 33/53 (2006.01); G01N 33/50 (2006.01)
CPC G01N 33/5076 (2013.01) [C07K 2319/80 (2013.01); C12Q 2600/142 (2013.01); G01N 2800/2835 (2013.01)] 22 Claims
 
1. A method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a condensate-associated molecule, the method comprising:
(a) contacting the compound with a cellular composition comprising one or more condensates or a cellular composition capable of forming one or more condensates, and
(b) determining the characteristic associated with the one or more condensates based on the number of the one or more condensates comprising the condensate-associated molecule, the cellular location of the one or more condensates, and the cellular distribution of the one or more condensates to identify the compound that modulates the characteristic associated with the one or more condensates,
wherein a modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more condensates.